Engineering affibody domains as anti-idiotypic masks for nivolumab-based prodrugs
Protein Engineering, Design and Selection · 2026
DOI: 10.1093/protein/gzag010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Protein Engineering, Design and Selection, 2026. Verfasst von Anna Mestre Borras und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Protein Science, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, SE-106 91, S…. Hauptthemen laut MEDLINE: Prodrugs, Nivolumab, Protein Engineering, Recombinant Fusion Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish Cancer Society, Swedish Research Council, Knut and Alice Wallenberg Foundation.
Abstract (Originalsprache)
Antibody prodrugs provide a strategy to reduce systemic toxicity by masking therapeutic antibodies until activation in specific physiological environments. Nivolumab, an anti-PD-1 checkpoint inhibitor used in cancer immunotherapy, can cause immune-related adverse events. As a first step toward a prodrug version of nivolumab, we screened an Escherichia coli affibody library using MACS and FACS, identifying affibodies that effectively mask its PD-1-binding regions. Deep sequencing revealed an unexpected enrichment of proline-rich variants, possibly mimicking a PD-1 loop. AlphaFold modeling suggested that these affibodies form interactions with nivolumab despite low alpha-helical content. Biosensor assays confirmed effective masking in a nivolumab prodrug format, with PD-1 binding restored upon proteolytic cleavage. These findings support further exploration of PD-1–mimicking affibodies as masking domains, advancing the development of more selective nivolumab prodrugs with improved safety profiles.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Protein Science, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, SE-106 91, Stockholm, Sweden.
ORCID-Profile: Anna Mestre Borras, Hanna Mehari, John Löfblom
Förderung
- Swedish Cancer Society
- Swedish Research Council
- Knut and Alice Wallenberg Foundation
- Wallenberg Center for Protein Research - WCPR
- Hjärnfonden
- Swedish Agency for Innovation VINNOVA
- CellNova center
Zitieren
APA
Mestre Borras, A., Mehari, H., Ståhl, S., & Löfblom, J. (2026). Engineering affibody domains as anti-idiotypic masks for nivolumab-based prodrugs. Protein Engineering, Design and Selection. https://doi.org/10.1093/protein/gzag010
Vancouver
Mestre Borras A, Mehari H, Ståhl S, Löfblom J. Engineering affibody domains as anti-idiotypic masks for nivolumab-based prodrugs. Protein Engineering, Design and Selection. 2026. doi:10.1093/protein/gzag010
BibTeX
@article{MestreBorras2026,
author = {Mestre Borras, Anna and Mehari, Hanna and Ståhl, Stefan and Löfblom, John},
title = {Engineering affibody domains as anti-idiotypic masks for nivolumab-based prodrugs},
journal = {Protein Engineering, Design and Selection},
year = {2026},
doi = {10.1093/protein/gzag010}
}
EUVIMED